Sarepta Therapeutics Inc (NASDAQ: SRPT) stock fell -0.11% on Monday to $83.06 against a previous-day closing price of $83.15. With 1.36 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.49 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $85.94 whereas the lowest price it dropped to was $82.62. The 52-week range on SRPT shows that it touched its highest point at $159.89 and its lowest point at $55.25 during that stretch. It currently has a 1-year price target of $139.22. Beta for the stock currently stands at 1.02.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SRPT was up-trending over the past week, with a rise of 4.26%, but this was down by -25.31% over a month. Three-month performance dropped to -26.94% while six-month performance fell -44.28%. The stock lost -23.99% in the past year, while it has lost -35.90% so far this year. A look at the trailing 12-month EPS for SRPT yields -7.83 with Next year EPS estimates of 2.77. For the next quarter, that number is -0.22. This implies an EPS growth rate of 15.52% for this year and 140.77% for next year.
Float and Shares Shorts:
At present, 93.55 million SRPT shares are outstanding with a float of 88.26 million shares on hand for trading. On Oct 30, 2023, short shares totaled 4.45 million, which was 4.75% higher than short shares on Sep 28, 2023. In addition to Mr. Douglas S. Ingram Esq. as the firm’s President, CEO & Director, Mr. Ian Michael Estepan serves as its Executive VP & CFO.
Through their ownership of 88.09% of SRPT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 5.17% of SRPT, in contrast to 48.72% held by mutual funds. Shares owned by individuals account for 40.34%. As the largest shareholder in SRPT with 9.05% of the stake, The Vanguard Group, Inc. holds 8,445,514 shares worth 8,445,514. A second-largest stockholder of SRPT, Janus Henderson Investors US LLC, holds 5,677,214 shares, controlling over 6.09% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in SRPT, holding 4,318,650 shares or 4.63% stake. With a 2.98% stake in SRPT, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,782,591 shares are owned by the mutual fund manager. The Vanguard Small Cap Index Fund, which owns about 2.45% of SRPT stock, is the second-largest Mutual Fund holder. It holds 2,285,507 shares valued at 153.84 million. Vanguard Health Care Fund holds 2.45% of the stake in SRPT, owning 2,283,656 shares worth 153.71 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SRPT since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SRPT analysts setting a high price target of $218.00 and a low target of $80.00, the average target price over the next 12 months is $134.24. Based on these targets, SRPT could surge 162.46% to reach the target high and fall by -3.68% to reach the target low. Reaching the average price target will result in a growth of 61.62% from current levels.
Summary of Insider Activity:
Insiders traded SRPT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 19 while that of sell transactions has risen to 18 over the past year. The total number of shares bought during that period was 132,193 while 23,518 shares were sold.